tbuckley/cabot-search huggingface dataset:
Association of an Active Choice Intervention in the Electronic Health Record Directed to Medical Assistants With Clinician Ordering and Patient Completion of Breast and Colorectal Cancer Screening Tests
Authors: Esther Y. Hsiang, Shivan J. Mehta, Dylan S. Small, Charles A. L. Rareshide, Christopher K. Snider, Susan C. Day, Mitesh S. Patel
Journal: JAMA Network Open (2019)

Early cancer detection can lead to improved outcomes, but cancer screening tests are often underused.To evaluate the association of an active choice intervention in the electronic health record directed to medical assistants with changes in clinician ordering and patient completion of breast and colorectal cancer screening tests.A retrospective quality improvement study was conducted among 69 916 patients eligible for breast or colorectal cancer screening at 25 primary care practices at the University of Pennsylvania Health System between September 1, 2014, and August 31, 2017. Data analysis was conducted from January 21 to July 8, 2019.From 2016 to 2017, 3 primary care practices at the University of Pennsylvania Health System implemented an active choice intervention in the electronic health record that prompted medical assistants to inform patients about cancer screening during check-in and template orders for clinicians to review during the visit.The primary outcome was clinician ordering of cancer screening tests. The secondary outcome was patient completion of cancer screening tests within 1 year of the primary care visit.The sample eligible for breast cancer screening comprised 26 269 women with a mean (SD) age of 60.4 (6.9) years; 15 873 (60.4%) were white and 7715 (29.4%) were black. The sample eligible for colorectal cancer screening comprised 43 647 patients with a mean (SD) age of 59.4 (7.5) years; 24 416 (55.9%) were women, 19 231 (44.1%) were men, 29 029 (66.5%) were white, and 9589 (22.0%) were black. For breast cancer screening, the intervention was associated with a significant increase in clinician ordering of tests (22.2 percentage points; 95% CI, 17.2-27.6 percentage points; P < .001) but no change in patient completion (0.1 percentage points; 95% CI, -4.0 to 4.3 percentage points; P = .45). For colorectal cancer screening, the intervention was associated with a significant increase in clinician ordering of tests (13.7 percentage points; 95% CI, 8.0-18.9 percentage points; P < .001) but no change in patient completion (1.0 percentage points; 95% CI, -3.2 to 4.6 percentage points; P = .36).An active choice intervention in the electronic health record directed to medical assistants was associated with a significant increase in clinician ordering of breast and colorectal cancer screening tests. However, it was not associated with a significant change in patient completion of either cancer screening test during a 1-year follow-up.
Homozygosity for -2518 G Allele Variant of MCP-1 Predisposes to Adverse Presentation and Outcome in Primary Myelofibrosis
Authors: Elena Masselli, Cecilia Carubbi, Giulia Pozzi, Antonio Percesepe, Rita Campanelli, Laura Villani, Giuliana Gobbi, Vittorio Rosti, Margherita Massa, Giovanni Barosi, Marco Vitale
Journal: Blood (2019)
A comprehensive genome variation map of melon identifies multiple domestication events and loci influencing agronomic traits
Authors: Guangwei Zhao, Qun Lian, Zhonghua Zhang, Qiushi Fu, Yuhua He, Shuangwu Ma, Valentino Ruggieri, Antonio J. Monforte, Pingyong Wang, Irene Julca, Huaisong Wang, Junpu Liu, Yong Xu, Runze Wang, Jiabing Ji, Zhihong Xu, Weihu Kong, Yang Zhong, Jianli Shang, Lara Pereira, Jason Argyris, Jian Zhang, Carlos Mayobre, Marta Pujol, Elad Oren, Diandian Ou, Jiming Wang, Dexi Sun, Shengjie Zhao, Yingchun Zhu, Na Li, Nurit Katzir, Amit Gur, Catherine Dogimont, Hanno Schaefer, Wei Fan, Abdelhafid Bendahmane, Zhangjun Fei, Michel Pitrat, Toni Gabaldón, Tao Lin, Jordi Garcia-Mas, Yongyang Xu, Sanwen Huang
Journal: Nature Genetics (2019)
Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Authors: Krish Patel, Jean-Marie Michot, Asher A. Chanan-Khan, Gilles A. Salles, Guillaume Cartron, Frederic Peyrade, Reda Bouabdallah, Erin G. Reid, Sheeba K. Thomas, William G. Wierda, David Liebowitz, John M. Pagel, Vincent Ribrag, M. Wayne Saville, Chelsea M. Johnson, Thomas Ly, Tycel J. Phillips
Journal: Blood (2019)
Abstract 10533: Molecular Magnetic Resonance Imaging of Activated Platelets Allows Noninvasive Detection of Early Inflammation in Myocarditis in Mice
Authors: Alexander Maier, Katharina Jakob, Dominik von Elverfeldt, Moritz Braig, Karlheinz Peter, Karin Klingel, Christoph Bode, Constantin von zur Mühlen
Journal: Circulation (2018)

Introduction: Platelets play an important role in inflammatory processes. To date, diagnostic gold standard for diagnosis of myocarditis is endomyocardial biopsy. However, it is an invasive method,...
Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL
Authors: Eugene C Kim, Jinzhen Fan, Christopher R Bolen, Alexandra Bazeos, Yanwen Jiang, Sandhya Balasubramanian, Rama Balakrishnan, Andrea Knapp, Kathryn Humphrey, Tina G Nielsen, Jeffrey M. Venstrom, Genevive Hernandez, Joseph N Paulson
Journal: Blood (2019)
Anaemia among men in India: a nationally representative cross-sectional study
Authors: Oliver Didzun, Jan-Walter De Neve, Ashish Awasthi, Manisha Dubey, Michaela Theilmann, Till Bärnighausen, Sebastian Vollmer, Pascal Geldsetzer
Journal: The Lancet Global Health (2019)

Population-based studies on anaemia in India have mostly focused on women and children, with men with anaemia receiving much less attention despite anaemia's adverse effect on health, wellbeing, and economic productivity. This study aimed to determine the national prevalence of anaemia among men in India; how the prevalence of anaemia in men varies across India among states and districts and by sociodemographic characteristics; and whether the geographical and sociodemographic variation in the prevalence of anaemia among men is similar to that among women to inform whether anaemia reduction efforts for men should be coupled with existing efforts for women.In this cross-sectional study, we analysed data from a nationally representative household survey carried out from January, 2015, to December, 2016, among men aged 15-54 years and women aged 15-49 years in all 29 states and seven Union Territories of India. Haemoglobin concentration was measured using the portable HemoCue Hb 201+ (HemoCue AB, Ängelholm, Sweden) and a capillary blood sample. In addition to disaggregating anaemia prevalence (separately in men and women) by state and age group, we used mixed-effects Poisson regression to determine individual-level and district-level predictors of anaemia.106 298 men and 633 305 women were included in our analysis. In men, the prevalence of any anaemia was 23·2% (95% CI 22·7-23·7), moderate or severe anaemia was 5·1% (4·9-5·4), and severe anaemia was 0·5% (0·5-0·6). An estimated 21·7% (20·9-22·5) of men with any degree of anaemia had moderate or severe anaemia compared with 53·2% (52·9-53·5) of women with any anaemia. Men aged 20-34 years had the lowest probability of having anaemia whereas anaemia prevalence among women was similar across age groups. State-level prevalence of any anaemia in men varied from 9·2% (7·7-10·9) in Manipur to 32·9% (31·0-34·7) in Bihar. The individual-level predictors of less household wealth, lower education, living in a rural area, smoking, consuming smokeless tobacco, and being underweight and the district-level predictors of living in a district with a lower rate of primary school completion, level of urbanisation, and household wealth were all associated with a higher probability of anaemia in men. Although some important exceptions were noted, district-level and state-level prevalence of anaemia among men correlated strongly with that among women.Anaemia among men in India is an important public health problem. Because of the similarities in the patterns of geographical and sociodemographic variation of anaemia between men and women, future efforts to reduce anaemia among men could target similar population groups as those targeted in existing efforts to reduce anaemia among women.Alexander von Humboldt Foundation.
Abstract 13753: Depression, Anxiety, and Attention Deficit Hyperactivity Disorder in Youth With Cardiac Arrhythmias: A Cross Sectional Comparative Study
Authors: Keila N Lopez, Vincent J Gonzalez, Katherine E Cutitta, John Shabosky, Mohammad F Bilal, Rachel T Kimbro
Journal: Circulation (2019)

Introduction: Higher rates of depression, anxiety, and attention deficit hyperactivity disorder (ADHD) have been described in patients with congenital heart disease (CHD). These data are limited fo...
ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS
Authors: Katherine Peters, Kendra Congdon, Gary Archer, Sarah Woodring, Denise Jaggers, Eric Lipp, Patrick Healy, James Herndon, Brian Soher, Gordana Vlahovic, Margaret Johnson, Dina Randazzo, Annick Desjardins, Henry Friedman, Allan Friedman, David Ashley, Hai Yan, John Sampson
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Low grade gliomas (LGGs) represent 10–15% of glial tumors in adults and while LGG patients have a better prognosis over high-grade gliomas, these cancers ultimately recur and transform to more aggressive tumors. Isocitrate dehydrogenase 1 (IDH1) is commonly mutated in LGG, and when mutated, it is the oncogenic driver by leading to the production of oncometabolite 2-hydroxyglutarate (2-HG). We developed a phase 1 study for recurrent resectable IDH1 mutant LGG utilizing a tumor-specific peptide vaccine targeting IDH1 mutant protein that spans the mutated region of IDHR132H (PEPIDH1M vaccine). METHODS We performed a phase 1, single-center, clinical trial in recurrent resectable IDH1 mutant WHO grade II glioma patients. Subjects received three PEPIDH1M vaccine q2wks and then proceeded to surgical resection. If subject’s tumor retained grade II status, then the subject proceeded with 12 cycles of daily TMZ (50 mg/m2 X 28 days) and PEPIDH1M vaccine (12 injections q4wks). If subject’s tumor transformed to grade III, then subject proceeded to radiation therapy (RT) with concurrent TMZ followed by 12 cycles of daily TMZ (50 mg/m2 X 28 days) and PEPIDH1M vaccine (12 injections q4wks). Primary endpoint was safety of PEPIDH1M vaccine in combination with adjuvant TMZ and/or XRT/TMZ and evaluable subjects needed to receive ≥6 PEPIDH1M vaccines. We assessed safety using CTCAE 4.03. RESULTS We enrolled 24 recurrent LGG subjects with mean age of 43.8 yrs (sd=11.4 yrs). Twenty subjects completed ≥6 PEPIDH1M vaccines. Most common related toxicity was grade 1 injection site reaction (N=20) and skin induration (n=17) with no grade 3–4 related toxicities. CONCLUSIONS PEPIDH1M vaccine in combination with surgical resection, daily TMZ and/or RT + TMZ with daily TMZ was safe and well tolerated in recurrent IDH1 mutant LGG. We are currently exploring secondary/correlative endpoints including immunogenicity of PEPIDH1M vaccine and magnetic resonance spectroscopy for 2-HG.
Association of Autofluorescence-Based Detection of the Parathyroid Glands During Total Thyroidectomy With Postoperative Hypocalcemia Risk
Authors: Fares Benmiloud, Gaelle Godiris-Petit, Régis Gras, Jean-Charles Gillot, Nicolas Turrin, Guillaume Penaranda, Séverine Noullet, Nathalie Chéreau, Jean Gaudart, Laurent Chiche, Stanislas Rebaudet
Journal: JAMA Surgery (2019)

Because inadvertent damage of parathyroid glands can lead to postoperative hypocalcemia, their identification and preservation, which can be challenging, are pivotal during total thyroidectomy.To determine if intraoperative imaging systems using near-infrared autofluorescence (NIRAF) light to identify parathyroid glands could improve parathyroid preservation and reduce postoperative hypocalcemia.This randomized clinical trial was conducted from September 2016 to October 2018, with a 6-month follow-up at 3 referral hospitals in France. Adult patients who met eligibility criteria and underwent total thyroidectomy were randomized. The exclusion criteria were preexisting parathyroid diseases.Use of intraoperative NIRAF imaging system during total thyroidectomy.The primary outcome was the rate of postoperative hypocalcemia (a corrected calcium <8.0 mg/dL [to convert to mmol/L, multiply by 0.25] at postoperative day 1 or 2). The main secondary outcomes were the rates of parathyroid gland autotransplantation and inadvertent parathyroid gland resection.A total of 245 of 529 eligible patients underwent randomization. Overall, 241 patients were analyzed for the primary outcome (mean [SD] age, 53.6 [13.6] years; 191 women [79.3%]): 121 who underwent NIRAF-assisted thyroidectomy and 120 who underwent conventional thyroidectomy (control group). The temporary postoperative hypocalcemia rate was 9.1% (11 of 121 patients) in the NIRAF group and 21.7% (26 of 120 patients) in the control group (between-group difference, 12.6% [95% CI, 5.0%-20.1%]; P = .007). There was no significant difference in permanent hypocalcemia rates (0% in the NIRAF group and 1.6% [2 of 120 patients] in the control group). Multivariate analyses accounting for center and surgeon heterogeneity and adjusting for confounders, found that use of NIRAF reduced the risk of hypocalcemia with an odds ratio of 0.35 (95% CI, 0.15-0.83; P = .02). Analysis of secondary outcomes showed that fewer patients experienced parathyroid autotransplantation in the NIRAF group than in the control group: respectively, 4 patients (3.3% [95% CI, 0.1%-6.6%) vs 16 patients (13.3% [95% CI, 7.3%-19.4%]; P = .009). The number of inadvertently resected parathyroid glands was significantly lower in the NIRAF group than in the control group: 3 patients (2.5% [95% CI, 0.0%-5.2%]) vs 14 patients (11.7% [95% CI, 5.9%-17.4%], respectively; P = .006).The use of NIRAF for the identification of the parathyroid glands may help improve the early postoperative hypocalcemia rate significantly and increase parathyroid preservation after total thyroidectomy.ClinicalTrials.gov Identifier: NCT02892253.
Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial
Authors: Robert J. Kreitman, Claire E. Dearden, Pier Luigi Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D le Coutre, Bjorn T. Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E Gladstone, Nataliya Kuptsova-Clarkson, Shiyao Liu, Priti Patel, Wyndham Wilson, Ira Pastan, Francis J. Giles
Journal: Blood (2019)
QOLP-06. EXISTENTIAL DISTRESS: UNADDRESSED CONCERNS FOR ADULT NEURO-ONCOLOGY PATIENTS
Authors: Ashlee Loughan, Sarah Braun, Mariya Husain, Farah Aslanzadeh, Rachel Boutte, Autumn Lanoye
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Primary brain tumor (PBT) patients may experience existential distress including fear of cancer recurrence and death anxiety; however, to date few have examined this issue. The objectives of this study were twofold: first, to systematically review PBT representation in the psycho-oncology literature on existential distress, and second, to preliminarily assess the prevalence and correlates of existential distress in a sample of PBT patients. PRIMARY OBJECTIVE METHODS/ RESULTS Three databases (PsycINFO, PubMed, and CINAHL) were systematically searched to identify articles measuring fear of cancer recurrence, fear of dying, or death anxiety in oncology patients. Included studies were examined to determine the frequency of PBT patients and identify exclusion criteria relevant to neuro-oncology. For studies including PBT patients, a more thorough data extraction was undertaken. Systematic searching found 336 studies meeting inclusion criteria (N=133,027). Eight studies (0.16% of the participants) included PBT patients. Exclusion criteria such as cognitive impairment and specific treatment parameters may have prohibited PBT patient participation. Studies including PBT patients used mixed methods with limited demographic analyses; existential distress was correlated with heightened psychological distress and poor quality of life. SECONDARY OBJECTIVE METHODS/ RESULTS A cross-sectional analysis of 81 PBT patients (20–86 years old) was conducted. Patients completed validated questionnaires of death anxiety, death distress, generalized anxiety, and depressive symptoms. Descriptive analyses, t-tests, chi-square, and Pearson correlations were conducted. Up to 79% of PBT patients endorsed death anxiety. These patients were significantly younger, more likely to be female, and have a low-grade brain tumor (p&lt; 0.05). Significant correlations were found between death anxiety and distress and symptoms of anxiety and depression (p&lt; 0.01). CONCLUSIONS PBT patients are underrepresented in existential psycho-oncology literature, despite preliminary findings suggesting prevalence of these concerns. Future investigations of existential distress in neuro-oncology is warranted to inform psychosocial screening and treatment for PBT patients.
Effect of Using Multiagent Versus Single Agent Chemotherapy on Overall Survival (OS) of Older Adults with Acute Myeloid Leukemia (AML)
Authors: Vijaya R. Bhatt, Valerie K Shostrom, Sarah A. Holstein, Zaid S. Al-Kadhimi, Lori J. Maness, Ann Berger, James O. Armitage, Krishna Gundabolu
Journal: Blood (2019)
Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus
Authors: Muthiah Vaduganathan, Gregg C. Fonarow, Stephen J. Greene, Adam D. DeVore, Nancy M. Albert, Carol I. Duffy, C. Larry Hill, John A. Spertus, Laine E. Thomas, Javed Butler
Journal: Journal of the American College of Cardiology (2019)
JAK2V617F Hematopoietic Stem and Progenitors Are More Resistant to Chronic Blockage of IL-10 Signaling in a Murine Model of Myeloproliferative Neoplasms
Authors: Hew Yeng Lai, Tiffany Trieu, Tiffany Han, Stefan Brooks, Brianna Craver, Gajalakshmi Ramanathan, Angela G. Fleischman
Journal: Blood (2019)
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era
Authors: Naveen Pemmaraju, Hagop M. Kantarjian, Joseph D. Khoury, Sanam Loghavi, Susan O'Brien, Jorge E. Cortes, Guillermo Garcia-Manero, Elias Jabbour, Srdan Verstovsek, Nitin Jain, Madeline Duvic, Phyu Aung, C. Cameron Yin, Sergej Konoplev, Keyur P. Patel, Sherry A. Pierce, Hannah Beird, Muzaffar H. Qazilbash, Marina Y Konopleva
Journal: Blood (2019)
Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients
Authors: Michelle Janania Martinez, Juan F Garza, Tyler W Snedden, Prathibha Surapaneni, Snegha Ananth, Jeremy Rawlings, David J Gregorio, Sushanth Kakarla, Qianqian Liu, Joel E Michalek, Adolfo Enrique Diaz
Journal: Blood (2019)
Genetics Helps to Find Synergy for Immune Checkpoint and Targeted Combination Therapies
Authors: Ludmila Prokunina-Olsson
Journal: Cancer Research (2019)

Abstract Checkpoint inhibitors, including anti-PD-L1 therapy, emerged as a treatment option for many cancer types, albeit with limited response rates. Combinations of immune-based and -targeted therapies are needed to achieve synergistic antitumor effects and provide much needed treatment personalization and improved response. Genetic alterations can be used as molecular drug targets and as biomarkers to select patients for specific therapies and their combinations. Fukumoto and colleagues present a promising example of this approach for the treatment of ovarian cancer with inactivating ARID1A mutations using a combination of the checkpoint and histone deacetylase inhibitors. See related article by Fukumoto et al., p. 5482
Abstract 13869: Statin Therapy Improves Fractional Catabolic Rate of LDL without Affecting Impaired VLDL and VLDL Remnant Catabolism in Homozygous FH Patient Due to PCSK9 Gene Mutation: Evidence from Kinetic Study with Stable Isotope
Authors: Masa-aki Kawashiri, Katsunori Ikewaki, Hayato Tada, Tohru Noguchi, Atsushi Nohara, Akihiro Inazu, Junji Kobayashi, Hiroshi Mabuchi, Masakazu Yamagishi
Journal: Circulation (2012)

Background: Statin decreases plasma low-density lipoprotein (LDL) cholesterol through activation of sterol regulatory element binding protein 2 (SREBP2) and ensuing induction of LDL receptor. SREBP...
The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors
Authors: Raisa Balbuena-Merle, Ronald G. Hauser, Matthew Karafin, Sylvia Tan, Bryan R Spencer, Nareg Roubinian, Yanyun Wu, Darrell Triulzi, Steven Kleinman, Jerry Gottschall, Christopher A. Tormey, Jeanne E. Hendrickson
Journal: Blood (2019)
Eomes and IL-10 Regulate Anti-Tumor Activity of T Cells in Chronic Lymphocytic Leukemia
Authors: Laura Llaó Cid, Philipp M Rößner, Ekaterina Lupar, Bola S Hanna, Jérôme Paggetti, Etienne Moussay, Dolors Colomer, Sascha Dietrich, Stephan Stilgenbauer, Ana Izcue, Martina Seiffert
Journal: Blood (2019)
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype–Guided Dosing
Authors: Smita S. Joshi, Daniel V.T. Catenacci, Theodore G. Karrison, Jaclyn D. Peterson, Mark M. Zalupski, Amikar Sehdev, James Wade, Ahad Sadiq, Vincent J. Picozzi, Andrea Amico, Robert Marsh, Mark F. Kozloff, Blase N. Polite, Hedy L. Kindler, Manish R. Sharma
Journal: Clinical Cancer Research (2019)

5-Fluorouracil (5-FU)/leucovorin, irinotecan, and nab-paclitaxel are all active agents in gastrointestinal cancers; the combination, FOLFIRABRAX, has not been previously evaluated. UDP Glucuronosyltransferase 1A1 (UGT1A1) clears SN-38, the active metabolite of irinotecan.